JP2021505554A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021505554A5 JP2021505554A5 JP2020529733A JP2020529733A JP2021505554A5 JP 2021505554 A5 JP2021505554 A5 JP 2021505554A5 JP 2020529733 A JP2020529733 A JP 2020529733A JP 2020529733 A JP2020529733 A JP 2020529733A JP 2021505554 A5 JP2021505554 A5 JP 2021505554A5
- Authority
- JP
- Japan
- Prior art keywords
- acid
- salt
- macular
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 65
- 239000002253 acid Substances 0.000 claims 50
- 150000002148 esters Chemical class 0.000 claims 28
- 230000000699 topical effect Effects 0.000 claims 21
- IKQCSJBQLWJEPU-UHFFFAOYSA-N 2,5-dihydroxybenzenesulfonic acid Chemical compound OC1=CC=C(O)C(S(O)(=O)=O)=C1 IKQCSJBQLWJEPU-UHFFFAOYSA-N 0.000 claims 16
- 230000001575 pathological effect Effects 0.000 claims 15
- 208000002780 macular degeneration Diseases 0.000 claims 14
- 208000017442 Retinal disease Diseases 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 206010038923 Retinopathy Diseases 0.000 claims 12
- 201000010099 disease Diseases 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 208000011580 syndromic disease Diseases 0.000 claims 12
- -1 alkali metal salt Chemical class 0.000 claims 10
- 208000035719 Maculopathy Diseases 0.000 claims 8
- 210000001328 optic nerve Anatomy 0.000 claims 7
- 230000002207 retinal effect Effects 0.000 claims 7
- 208000010412 Glaucoma Diseases 0.000 claims 6
- 206010064930 age-related macular degeneration Diseases 0.000 claims 6
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims 6
- 201000006321 fundus dystrophy Diseases 0.000 claims 6
- 208000038015 macular disease Diseases 0.000 claims 6
- 210000001525 retina Anatomy 0.000 claims 5
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 4
- 208000009702 Optic Disk Drusen Diseases 0.000 claims 4
- 208000014139 Retinal vascular disease Diseases 0.000 claims 4
- 208000034699 Vitreous floaters Diseases 0.000 claims 4
- 229910052783 alkali metal Inorganic materials 0.000 claims 4
- 150000001412 amines Chemical class 0.000 claims 4
- 210000003161 choroid Anatomy 0.000 claims 4
- 206010059245 Angiopathy Diseases 0.000 claims 3
- 239000012530 fluid Substances 0.000 claims 3
- 241000252073 Anguilliformes Species 0.000 claims 2
- 206010003694 Atrophy Diseases 0.000 claims 2
- 229920000298 Cellophane Polymers 0.000 claims 2
- 208000016615 Central areolar choroidal dystrophy Diseases 0.000 claims 2
- 208000033825 Chorioretinal atrophy Diseases 0.000 claims 2
- 208000033810 Choroidal dystrophy Diseases 0.000 claims 2
- 208000008515 Choroidal sclerosis Diseases 0.000 claims 2
- 206010010541 Congenital melanosis Diseases 0.000 claims 2
- 201000001353 Doyne honeycomb retinal dystrophy Diseases 0.000 claims 2
- 208000037312 Familial drusen Diseases 0.000 claims 2
- 108700000201 Hyaloideoretinal degeneration of Wagner Proteins 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000032578 Inherited retinal disease Diseases 0.000 claims 2
- 208000033463 Ischaemic neuropathy Diseases 0.000 claims 2
- 208000001344 Macular Edema Diseases 0.000 claims 2
- 206010025415 Macular oedema Diseases 0.000 claims 2
- 206010025421 Macule Diseases 0.000 claims 2
- 206010069385 Ocular ischaemic syndrome Diseases 0.000 claims 2
- 206010030113 Oedema Diseases 0.000 claims 2
- 208000036584 Optic disc drusen Diseases 0.000 claims 2
- 206010061323 Optic neuropathy Diseases 0.000 claims 2
- 241000206607 Porphyra umbilicalis Species 0.000 claims 2
- 206010064714 Radiation retinopathy Diseases 0.000 claims 2
- 201000007737 Retinal degeneration Diseases 0.000 claims 2
- 208000032430 Retinal dystrophy Diseases 0.000 claims 2
- 206010038910 Retinitis Diseases 0.000 claims 2
- 206010038926 Retinopathy hypertensive Diseases 0.000 claims 2
- 206010047249 Venous thrombosis Diseases 0.000 claims 2
- 208000034698 Vitreous haemorrhage Diseases 0.000 claims 2
- 208000022482 Wagner disease Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 230000037444 atrophy Effects 0.000 claims 2
- QGNBTYAQAPLTMX-UHFFFAOYSA-L calcium dobesilate Chemical class [Ca+2].OC1=CC=C(O)C(S([O-])(=O)=O)=C1.OC1=CC=C(O)C(S([O-])(=O)=O)=C1 QGNBTYAQAPLTMX-UHFFFAOYSA-L 0.000 claims 2
- 230000007850 degeneration Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 230000006806 disease prevention Effects 0.000 claims 2
- 230000004438 eyesight Effects 0.000 claims 2
- 230000002008 hemorrhagic effect Effects 0.000 claims 2
- 208000014188 hereditary optic neuropathy Diseases 0.000 claims 2
- 201000001948 hypertensive retinopathy Diseases 0.000 claims 2
- 208000017532 inherited retinal dystrophy Diseases 0.000 claims 2
- 230000000366 juvenile effect Effects 0.000 claims 2
- 201000010230 macular retinal edema Diseases 0.000 claims 2
- 208000001491 myopia Diseases 0.000 claims 2
- 230000004379 myopia Effects 0.000 claims 2
- 201000005799 nutritional optic neuropathy Diseases 0.000 claims 2
- 210000003733 optic disk Anatomy 0.000 claims 2
- 201000002166 optic papillitis Diseases 0.000 claims 2
- 239000000790 retinal pigment Substances 0.000 claims 2
- 210000003786 sclera Anatomy 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 208000029517 toxic amblyopia Diseases 0.000 claims 2
- 208000000318 vitreous detachment Diseases 0.000 claims 2
- 206010002329 Aneurysm Diseases 0.000 claims 1
- 208000037060 Hyalosis asteroid Diseases 0.000 claims 1
- 206010023126 Jaundice Diseases 0.000 claims 1
- 206010064145 Retinal aneurysm Diseases 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 229960005438 calcium dobesilate Drugs 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000003511 endothelial effect Effects 0.000 claims 1
- 239000003889 eye drop Substances 0.000 claims 1
- 229940012356 eye drops Drugs 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000032253 retinal ischemia Diseases 0.000 claims 1
- 230000004286 retinal pathology Effects 0.000 claims 1
- 239000008009 topical excipient Substances 0.000 claims 1
- 210000004127 vitreous body Anatomy 0.000 claims 1
- 208000026726 vitreous disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17382832 | 2017-12-04 | ||
| EP17382832.8 | 2017-12-04 | ||
| PCT/EP2018/082999 WO2019110416A1 (en) | 2017-12-04 | 2018-11-29 | Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021505554A JP2021505554A (ja) | 2021-02-18 |
| JP2021505554A5 true JP2021505554A5 (enExample) | 2022-01-06 |
Family
ID=60673756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020529733A Pending JP2021505554A (ja) | 2017-12-04 | 2018-11-29 | 眼の後部の疾患を治療するためのドベシル酸を含む眼科用局所組成物 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20200390729A1 (enExample) |
| EP (1) | EP3720428B1 (enExample) |
| JP (1) | JP2021505554A (enExample) |
| KR (1) | KR102756155B1 (enExample) |
| CN (1) | CN111542316A (enExample) |
| AU (1) | AU2018378981B2 (enExample) |
| BR (1) | BR112020011160A2 (enExample) |
| CA (1) | CA3083835A1 (enExample) |
| CL (1) | CL2020001426A1 (enExample) |
| DK (1) | DK3720428T3 (enExample) |
| ES (1) | ES2941036T3 (enExample) |
| FI (1) | FI3720428T3 (enExample) |
| HR (1) | HRP20230319T1 (enExample) |
| HU (1) | HUE061852T2 (enExample) |
| MA (1) | MA50991B1 (enExample) |
| MX (1) | MX2020005809A (enExample) |
| MY (1) | MY205498A (enExample) |
| PH (1) | PH12020550722A1 (enExample) |
| PL (1) | PL3720428T3 (enExample) |
| PT (1) | PT3720428T (enExample) |
| SG (1) | SG11202004940VA (enExample) |
| SI (1) | SI3720428T1 (enExample) |
| WO (1) | WO2019110416A1 (enExample) |
| ZA (1) | ZA202003944B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT202300017430A1 (it) * | 2023-08-22 | 2025-02-22 | Service Biotech srl | Soluzione oftalmica in forma di collirio contenente una isoforma umana ricombinante di manganese superossido dismutasi (rmnsod) per la cura di patologie dell’occhio |
| CN117257963B (zh) * | 2023-11-02 | 2024-07-16 | 广州准优生物科技有限公司 | 含脐带间充质干细胞外泌体的眼用药剂及其制备方法和用途 |
| CN117643573B (zh) * | 2024-01-29 | 2024-05-03 | 天津医科大学眼科医院 | 一种可递送药物至眼后节的纳米滴眼液及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE51421B1 (en) * | 1980-08-01 | 1986-12-24 | Smith & Nephew Ass | Ophthalmic compositions containing triamterene |
| US9198886B2 (en) * | 2006-08-16 | 2015-12-01 | Pedro Cuevas Sánchez | Use of 2,5-dihydroxybenzene for the treatment of ocular diseases |
| SG11201402347YA (en) * | 2011-11-30 | 2014-06-27 | Xigen Inflammation Ltd | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of dry eye syndrome |
| ES2632012T3 (es) * | 2012-02-02 | 2017-09-07 | Invesfovea S.L. | Uso del ácido 2,5-dihidroxibenceno sulfonato para el tratamiento de la degeneración macular relacionada con la edad |
| CN104334575A (zh) * | 2012-03-05 | 2015-02-04 | 韦恩州立大学 | 通道视蛋白-2(Chop2)突变的鉴定及使用方法 |
| EP2841454A1 (en) * | 2012-04-24 | 2015-03-04 | ThromboGenics N.V. | Anti-pdgf-c antibodies |
| EP2875811A1 (en) | 2013-11-26 | 2015-05-27 | Luis Antonio Outeirino Miguez | Use of dobesilate for treating ocular haemorrhages |
-
2018
- 2018-11-29 KR KR1020207018983A patent/KR102756155B1/ko active Active
- 2018-11-29 CA CA3083835A patent/CA3083835A1/en active Pending
- 2018-11-29 WO PCT/EP2018/082999 patent/WO2019110416A1/en not_active Ceased
- 2018-11-29 BR BR112020011160-0A patent/BR112020011160A2/pt unknown
- 2018-11-29 DK DK18811023.3T patent/DK3720428T3/da active
- 2018-11-29 PL PL18811023.3T patent/PL3720428T3/pl unknown
- 2018-11-29 CN CN201880082202.1A patent/CN111542316A/zh active Pending
- 2018-11-29 US US16/770,027 patent/US20200390729A1/en active Pending
- 2018-11-29 MY MYPI2020002628A patent/MY205498A/en unknown
- 2018-11-29 ES ES18811023T patent/ES2941036T3/es active Active
- 2018-11-29 EP EP18811023.3A patent/EP3720428B1/en active Active
- 2018-11-29 AU AU2018378981A patent/AU2018378981B2/en active Active
- 2018-11-29 SG SG11202004940VA patent/SG11202004940VA/en unknown
- 2018-11-29 JP JP2020529733A patent/JP2021505554A/ja active Pending
- 2018-11-29 MX MX2020005809A patent/MX2020005809A/es unknown
- 2018-11-29 MA MA50991A patent/MA50991B1/fr unknown
- 2018-11-29 FI FIEP18811023.3T patent/FI3720428T3/fi active
- 2018-11-29 PT PT188110233T patent/PT3720428T/pt unknown
- 2018-11-29 SI SI201830869T patent/SI3720428T1/sl unknown
- 2018-11-29 HU HUE18811023A patent/HUE061852T2/hu unknown
- 2018-11-29 HR HRP20230319TT patent/HRP20230319T1/hr unknown
-
2020
- 2020-05-27 PH PH12020550722A patent/PH12020550722A1/en unknown
- 2020-05-28 CL CL2020001426A patent/CL2020001426A1/es unknown
- 2020-06-29 ZA ZA2020/03944A patent/ZA202003944B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5421272B2 (ja) | 眼病治療のための組成物及び方法 | |
| US20200323685A1 (en) | Sustained release delivery of active agents to treat glaucoma and ocular hypertension | |
| JP2021505554A5 (enExample) | ||
| JP2008538215A5 (enExample) | ||
| JP2006503913A5 (enExample) | ||
| CN111372576A (zh) | 用于治疗眼部病症的组合物和方法 | |
| US20140025022A1 (en) | Drug delivery system and methods of treating open angle glaucoma and ocular hypertension | |
| US20060111388A1 (en) | Phenanthroline and derivatives thereof used to lower intraocular pressure in an affected eye | |
| WO2012015998A2 (en) | Preservative free bimatoprost and timolol solutions | |
| HRP20230319T1 (hr) | Očni topikalni pripravak koji sadrži dobesilnu kiselinu, namijenjen liječenju bolesti stražnjeg segmenta oka | |
| WO2008124828A1 (en) | Methods for treating vascular disruption disorders | |
| CN111315369A (zh) | 用于治疗眼部病症和皮肤疾病的化合物、组合物和方法 | |
| Bagnis et al. | Antiglaucoma drugs: The role of preservative-free formulations | |
| Omoti | A review of the choice of therapy in primary open angle glaucoma | |
| CN104758249A (zh) | 用于眼药物递送的稳定的脂质体制剂 | |
| ES2624446T3 (es) | Compuestos donantes de óxido nítrico a base de quinona para uso oftalmológico | |
| GB2432526A (en) | Use of ifenprodil for the treatment of ophthalmic diseases | |
| JP2012505928A5 (enExample) | ||
| RU2642731C1 (ru) | Способ хирургического лечения открытоугольной глаукомы у пациентов с артифакией | |
| JPWO2019191525A5 (enExample) | ||
| CN115427046A (zh) | 用于治疗眼部疾病的叶酸类物质制剂 | |
| RU2607291C1 (ru) | Способ лечения первичной глаукомы у больных с сопутствующей артериальной гипертензией | |
| Yadgari et al. | Elevated intraocular pressure after pars plana vitrectomy: a review | |
| US20240024348A1 (en) | Methods and compositions for the treatment of glaucoma and related conditions | |
| JP2009517375A (ja) | 眼の疾患の治療 |